Work

Real-world outcomes of dupilumab therapy in moderate-to-severe atopic dermatitis patients: an observational retrospective study in Gulf countries

Year: 2025

Type: article

Abstract: OBJECTIVES: Dupilumab has demonstrated strong efficacy and safety in clinical trials for atopic dermatitis (AD), but real-world data from the Greater Gulf region remain limited. This study aimed to evaluate the real-world effectiveness and safety of dupilumab in adolescents and adults with moderate-to-severe AD in Saudi Arabia and the United Arab Emirates. METHODS: A retrospective observational study was conducted in adolescents and adults (≥12 years) with moderate-to-severe AD, who had received dupilumab for one to three years. Clinical outcomes were assessed using SCORing Atopic Dermatitis (SCORAD) and the Dermatology Life Quality Index (DLQI), while safety was evaluated through reported adverse events (AEs). RESULTS: Ninety-five patients were eligible, with a mean age of 29.3 years, and 52.6% were males. The mean baseline SCORAD score was 49.9, which decreased markedly to 21.5 after one month, 12.7 after three months, and 14.1 at six months. At six months, data were available for 71 patients, of whom 76% achieved SCORAD-50 and 52.1% achieved SCORAD-75. Reported AEs were generally mild, the most frequent being dry eyes (14.7%), dry eyes with pruritus (8.4%), and facial erythema (6.3%). No serious AEs or treatment discontinuations were recorded. CONCLUSION: Dupilumab demonstrated sustained clinical improvements and favorable safety. These findings reinforce the results of previous real-world studies and Randomized Controlled Trials.

Source: Journal of Dermatological Treatment

DOI: 10.1080/09546634.2025.2572650